{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:34:10Z","timestamp":1791380050168,"version":"4.3.3"},"reference-count":55,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose of Review\nThis is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this purpose.\nRecent Findings\nExcessive daytime sleepiness leads to worse quality of life, a medical sequela and significant economic cost. There are multiple phenotypes of excessive daytime sleepiness depending on the comorbidity making treatment challenging. Due to the complexity of etiology there is not a cure for this ailment. Solriamfetol is a norepinephrine\/dopamine dual reuptake antagonist that can be used to manage daytime sleepiness. Solriamfetol was first approved by the FDA in 2018 for use in excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy. Ongoing literature has proved this drug to be a safe and effective alternative pharmacotherapy.\nSummary\nRecent epidemiological data estimate up to one-third of the general adult population suffers from excessive daytime sleepiness. There is no cure to daytime somnolence and current pharmacotherapeutic regimens have worrisome side effect profiles. Solriamfetol is a new class of drug that offers a safe and effective alternative option for clinical providers treating excessive daytime sleepiness.<\/jats:p>","DOI":"10.64719\/pb.4484","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"65-86","source":"Crossref","is-referenced-by-count":5,"title":["A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness"],"prefix":"10.64719","volume":"54","author":[{"given":"Mitchell C.","family":"Fuller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Pysick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tondryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Carlton R, Lunacsek O, Regan T, Carroll CA. Healthcare costs among patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy. Am Heal Drug Benefits. 2014;7(6):334\u2013339. [Internet] [cited 2020 Oct 8] Available from: http:\/\/www.AHDBonline.com."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bogan RK. Getting serious about excessive sleepiness. Sleep Health. 2019;5:319. [Internet] Elsevier Inc. [cited 2020 Oct 8] Available from: http:\/\/www.sleephealthjournal.org\/article\/S235272181930141X\/fulltext.","DOI":"10.1016\/j.sleh.2019.07.005"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Patil SP, Schneider H, Schwartz AR, Smith PL. Adult obstructive sleep apnea: Pathophysiology and diagnosis. Chest. 2007;132(1):325\u2013337.","DOI":"10.1378\/chest.07-0040"},{"key":"#cr-split#-ref4.1","doi-asserted-by":"crossref","unstructured":"Adamantidis AR, Schmidt MH, Carter ME, Burdakov D, Peyron C, Scammell TE. A circuit perspective on narcolepsy. Sleep. 2020;43","DOI":"10.1093\/sleep\/zsz296"},{"key":"#cr-split#-ref4.2","unstructured":"(5) [Internet] [cited 2020 Oct 8] Available from: http:\/\/creativecommons."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Carbonell L. Treatment of excessive daytime sleepiness in patients with narcolepsy. Current Treatment Options in Neurology. 2019;21:57. [Internet] Current Science Inc. [cited 2020 Oct 8] Available from: https:\/\/link.springer.com\/article\/10.1007\/s11940-019-0595-9.","DOI":"10.1007\/s11940-019-0595-9"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"During E, Kushida C. Clinical sleep medicine: A comprehensive guide for mental health and other \u2026 - Google Livros. 2020","DOI":"10.1176\/appi.books.9781615379507"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S et al. Sleep apnea: Types, mechanisms, and clinical cardiovascular consequences. Journal of the American College of Cardiology. 2017;69:841\u2013858. Elsevier USA.","DOI":"10.1016\/j.jacc.2016.11.069"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep. 2003;26(1):15\u201319.","DOI":"10.1093\/sleep\/26.1.15"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Salman LA, Shulman R, Cohen JB. Current Cardiology Reports. Vol. 22. Springer; 2020. Obstructive sleep apnea, hypertension, and cardiovascular risk: Epidemiology, pathophysiology, and management; pp. 1\u20139.","DOI":"10.1007\/s11886-020-1257-y"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hou H, Zhao Y, Yu W, Dong H, Xue X, Ding J et al. Correspondence to: Association of obstructive sleep apnea with hypertension: A systematic review and meta-analysis. 2018;8(1):10405.","DOI":"10.7189\/jogh.08.010405"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: Population study. Br Med J. 2000;320(7233):479\u2013482.","DOI":"10.1136\/bmj.320.7233.479"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med. 2005;352(12)","DOI":"10.1056\/NEJMoa041832"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Blackwell JN, Walker M, Stafford P, Estrada S, Adabag S, Kwon Y. Sleep apnea and sudden cardiac death. Circ Reports. 2019;1(12):568\u2013574.","DOI":"10.1253\/circrep.CR-19-0085"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Heffner JE, Rozenfeld Y, Kai M, Stephens EA, Brown LK. Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. Chest. 2012;141(6):1414\u20131421.","DOI":"10.1378\/chest.11-1945"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Garbarino S, Guglielmi O, Sanna A, Mancardi GL, Magnavita N. Risk of occupational accidents in workers with obstructive sleep apnea: Systematic review and meta-Analysis. Sleep. 2016;39(6):1211\u20131218.","DOI":"10.5665\/sleep.5834"},{"key":"ref16","unstructured":"Slowik JM, Collen JF, Yow AG. Narcolepsy. StatPearls. 2020"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kallweit U, Schmidt M, Bassetti CL. Patient-reported measures of narcolepsy: The need for better assessment. J Clin Sleep Med. 2017;13(5):737\u2013744.","DOI":"10.5664\/jcsm.6596"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rosenberg RS, Van Hout S. The american academy of sleep medicine inter-scorer reliability program: Respiratory events. J Clin Sleep Med. 2014;10(4):447\u2013454.","DOI":"10.5664\/jcsm.3630"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U. Nature Reviews Neurology. Vol. 15. Nature Publishing Group; 2019. Narcolepsy\u2014clinical spectrum, aetiopathophysiology, diagnosis and treatment; pp. 519\u2013539.","DOI":"10.1038\/s41582-019-0226-9"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yeh J-Y, Shyu Y-C, Lee S-Y, Yuan S-S, Yang C-J, Yang K-C et al. Comorbidity of narcolepsy and psychotic disorders: A nationwide population-based study in Taiwan. Front Psychiatry. 2020;11:1.","DOI":"10.3389\/fpsyt.2020.00205"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Lee MJ, Lee SY, Yuan SS, Yang CJ, Yang KC, Lee TL et al. Comorbidity of narcolepsy and depressive disorders: A nationwide population-based study in Taiwan. Sleep Med. 2017;39:95\u2013100.","DOI":"10.1016\/j.sleep.2017.07.022"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Nordstrand SEH, Juvodden HT, Viste R, Rootwelt T, Karlsen TI, Thorsby PM et al. Obesity and other medical comorbidities among NT1 patients after the Norwegian H1N1 influenza epidemic and vaccination campaign. Sleep. 2020;43(5)","DOI":"10.1093\/sleep\/zsz277"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Straat ME, Schinkelshoek MS, Fronczek R, Lammers GJ, Rensen PCN, Boon MR. Role of brown adipose tissue in adiposity associated with narcolepsy Type 1. Frontiers in Endocrinology. Frontiers Media S.A.. 2020;11:145.","DOI":"10.3389\/fendo.2020.00145"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Chang ET, Lin CL, Chen SF, Hsu CY, Shen YC. Risk of bone fractures in patients with narcolepsy: a nationwide population-based cohort study. Sleep Med. 2020;70:55\u201359.","DOI":"10.1016\/j.sleep.2020.02.015"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Martinez-Orozco FJ, Vicario JL, De Andres C, Fernandez-Arquero M, Peraita-Adrados R. Comorbidity of Narcolepsy Type 1 With autoimmune diseases and other immunopathological disorders: A case-control study. J Clin Med Res. 2016;8(7):495\u2013505.","DOI":"10.14740\/jocmr2569w"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Spicuzza L, Caruso D, Di Maria G. Obstructive sleep apnoea syndrome and its management. Ther Adv Chronic Dis. 2015;6(5):273\u2013285.","DOI":"10.1177\/2040622315590318"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Osman AM, Carter SG, Carberry JC, Eckert DJ. Nature and Science of Sleep. Vol. 10. Dove Medical Press Ltd; 2018. Obstructive sleep apnea: Current perspectives; pp. 21\u201334.","DOI":"10.2147\/NSS.S124657"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Taranto-Montemurro L, Sands SA, Edwards BA, Azarbarzin A, Marques M, De Melo C et al. Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur Respir J. 2016;48(5):1340\u20131350.","DOI":"10.1183\/13993003.00823-2016"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Carberry JC, Fisher LP, Grunstein RR, Gandevia SC, McKenzie DK, Butler JE et al. Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: Paradoxical effects of zolpidem. Eur Respir J. 2017;50(6)","DOI":"10.1183\/13993003.01344-2017"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain clinical implications. JAMA\u2014J Am Med Assoc. 2009;301(11):1148\u20131154.","DOI":"10.1001\/jama.2009.351"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Sleep Medicine Reviews. Vol. 43. W.B. Saunders Ltd; 2019. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy; pp. 23\u201336.","DOI":"10.1016\/j.smrv.2018.09.006"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Walsh JK, Hall-Porter JM, Griffin KS, Dodson ER, Forst EH, Curry DT et al. Enhancing slow wave sleep with sodium oxybate reduces the behavioral and physiological impact of sleep loss. Sleep. 2010;33(9):1217\u20131225.","DOI":"10.1093\/sleep\/33.9.1217"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Black J, Emsellem H, Feldman N, Hagaman M, Hayduk R, Kathawalla S et al. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119\u2013123.","DOI":"10.1016\/j.sleep.2003.11.002"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Mayer G, Plazzi G, Iranzo \u00c1, Ortega-Alb\u00e1s J, Quinnell T, Pesch H et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: A postauthorization, noninterventional surveillance study. Sleep. 2018;41(9)","DOI":"10.1093\/sleep\/zsy128"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Morse AM, Kelly-Pieper K, Kothare S V. Management of excessive daytime sleepiness in narcolepsy with Baclofen. Pediatr Neurol. 2019;93:39\u201342.","DOI":"10.1016\/j.pediatrneurol.2018.10.020"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R et al. Effect of Oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with Narcolepsy: A phase 2b study. Sleep. 2016;39(7):1379\u20131387.","DOI":"10.5665\/sleep.5968"},{"key":"ref37","unstructured":"Veteran Population Projections. [cited 2020 Aug 17]. Available from: https:\/\/www.va.gov\/vetdata\/docs\/Demographics\/New_Vetpop_Model\/Vetpop_Infographic2020.pdf."},{"key":"ref38","unstructured":"Drugs@FDA: FDA-Approved Drugs"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Schneider L. Neurobiology and neuroprotective benefits of sleep. Contin Lifelong Learn Neurol. 2020;26(4):848\u2013870.","DOI":"10.1212\/CON.0000000000000878"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367\u2013376.","DOI":"10.1124\/jpet.118.248120"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Abad V, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39\u201357.","DOI":"10.2147\/NSS.S103467"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Watson CJ, Baghdoyan HA, Lydic R. Neuropharmacology of sleep and wakefulness. Sleep Medicine Clinics. 2010","DOI":"10.1016\/j.jsmc.2010.08.003"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Zomorodi K, Kankam M, Lu Y. A Phase I, Randomized, Crossover, open-label study of the pharmacokinetics of Solriamfetol (JZP-110) in healthy adult subjects with and without food. Clin Ther. 2019","DOI":"10.1016\/j.clinthera.2018.12.001"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Zomorodi K, Chen D, Lee L, Lasseter K, Marbury T. Single-Dose Pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019;59(8):1120\u20131129.","DOI":"10.1002\/jcph.1402"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Thorpy MJ. Recently approved and upcoming treatments for Narcolepsy. CNS Drugs. 2020","DOI":"10.1007\/s40263-019-00689-1"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102\u20131108.","DOI":"10.1016\/j.sleep.2015.05.013"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Malhotra A, Shapiro C, Pepin J-L, Hedner J, Ahmed M, Foldvary-Schaefer N et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. 2019","DOI":"10.1093\/sleep\/zsz220"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): A randomized controlled trial. Am J Respir Crit Care Med. 2019;199(11):1421\u20131431.","DOI":"10.1164\/rccm.201806-1100OC"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359\u2013370.","DOI":"10.1002\/ana.25423"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G et al. Solriamfetol for the treatment of excessive daytime sleepiness in participants with Narcolepsy with and without Cataplexy: Subgroup analysis of efficacy and safety data by cataplexy status in a randomized controlled trial. CNS Drugs. 2020;34(7):773\u2013784.","DOI":"10.1007\/s40263-020-00744-2"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351\u20131361.","DOI":"10.1177\/0269881118796814"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Weaver TE, Drake CL, Benes H, Stern T, Maynard J, Thein SG et al. Effects of Solriamfetol on Quality-of-Life measures from a 12-Week Phase 3 randomized controlled trial. Ann Am Thorac Soc. 2020;17(8):998\u20131007.","DOI":"10.1513\/AnnalsATS.202002-136OC"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G et al. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. Sleep Med. 2020;67:128\u2013136.","DOI":"10.1016\/j.sleep.2019.11.1250"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Abad VC, Guilleminault C. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Rev Respir Med. 2018;12(12):1007\u20131019. [Internet] [cited 2020 Oct 8] Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/17476348.2018.1541742.","DOI":"10.1080\/17476348.2018.1541742"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:32:19Z","timestamp":1791315139000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/a-comprehensive-review-of-solriamfetol-to-treat-excessive-daytime-sleepiness\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4484","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}